A Prediction Model for Contralateral Central Neck Lymph Node Metastases in Unilateral Papillary Thyroid Cancer

Table 1

Demographics and clinicopathological characteristics of 250 unilateral papillary thyroid carcinoma patients.

Characteristics	Number (%)
No. of patients	250 (100)
Sex
Male/female	49 (19.6)/201 (80.4)
Age (mean ± SD, (range)), years	39.67 ± 11.36 (18–70)
≥55/<55	25 (10.0)/225 (90.0)
Primary tumor size (mean ± SD), mm	15.95 ± 10.25
≤10/>10	95 (38.0)/155 (62.0)
Hashimoto’s thyroiditis
Yes/No	120 (48.0)/130 (52.0)
BRAF^V600Emutation
Positive/negative	179 (71.6)/71 (28.4)
Multifocality
Yes/No	21 (8.4)/229 (91.6)
Capsular invasion
Present/absent	83 (33.2)/167 (66.8)
ETE
Present/absent	58 (23.2)/192 (76.8)
cN0/cN1	130 (52.0)/120 (48.0)
CLNM	157 (62.8)
Bi-CLNM	72 (45.9)
Only ipsi-CLNM	82 (52.2)
Skip-CLNM	3 (1.9)
Number of CLNM (mean ± SD, range)
Con-CLNM	2.99 ± 2.54 (1–15)
Ipsi-CLNM	4.12 ± 3.30 (1–20)
Ipsi-LLNM	86 (34.4)
With con-CLNM	48 (55.8)

Abbreviations: bi-CLNM, bilateral central lymph node metastasis; CLNM, central lymph node metastasis; cN0, clinical N0; cN1, clinical N1; con-CLNM, contralateral central lymph node metastasis; ETE, extrathyroid extension; ipsi-CLNM, ipsilateral central lymph node metastasis; ipsi-LLNM, ipsilateral lateral lymph node metastasis; PTC, papillary thyroid carcinoma; SD, standard deviation; Skip-CLNM, contralateral skip central lymph node metastasis.